Download PDF
kleintier konkret 2021; 24(01): 8-16
DOI: 10.1055/a-1327-9818
Onkologie
Hund

Mastzelltumoren der Haut beim Hund – Erste Erfahrungen zum Einsatz von Tigilanoltiglat

Meike Horn
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Für die Therapie des Mastzelltumors beim Hund steht seit einigen Monaten eine neue Therapie zur Verfügung: die intratumorale Tigilanoltiglat-Injektion. Informieren Sie sich über etablierte Therapieoptionen sowie über das Procedere und erste Erfahrungen mit der neuartigen Therapie.

Publication History

Article published online:
19 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Brodey RS. Canine and feline neoplasia. Adv Vet Sci Comp Med 1970; 14: 309-354
    PubMedGoogle Scholar
  • 2 Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1986; 142 (01) 1-19
    CrossrefPubMedGoogle Scholar
  • 3 Śmiech A, Ślaska B, Łopuszyński W. et al. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Acta Vet Scand 2018; 60 (01) 70
    CrossrefPubMedGoogle Scholar
  • 4 Shoop SJW, Marlow S, Church DB. et al. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol 2015; 2 (01) 1
    CrossrefPubMedGoogle Scholar
  • 5 London CA, Thamm DH. Mast Cell Tumors. In: Withrow SJ, Vail DM, Page RL. eds. Withrow and MacEwenʼs Small Animal Clinical Oncology. 5th ed. Riverport Lane St. Louis, Missouri: Elsevier Saunders; 2013: 335-355
    Google Scholar
  • 6 Mullins MN, Dernell WS, Withrow SJ. et al. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998–2004). J Am Vet Med Assoc 2006; 228 (01) 91-95
    CrossrefPubMedGoogle Scholar
  • 7 Pelt DR, Fowler JD, Leighton FA. Multiple cutaneous mast cell tumors in a dog: a case report and brief review. Can Vet J 1986; 27 (07) 259-263
    PubMedGoogle Scholar
  • 8 Baker-Gabb M, Hunt GB, France MP. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. Aust Vet J 2003; 81 (37) 732-738
    CrossrefPubMedGoogle Scholar
  • 9 Kiupel M, Camus M. Diagnosis and prognosis of canine cutaneous mast cell tumors. Vet Clin North Am Small Anim Pract 2019; 49 (05) 819-836
    CrossrefPubMedGoogle Scholar
  • 10 Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumour: morphologic grading and survival time in 83 dogs. Vet Pathol 1984; 21 (01) 469-474
    CrossrefPubMedGoogle Scholar
  • 11 Kiupel M, Webster JD, Bailey KL. et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011; 48 (01) 147-155
    CrossrefPubMedGoogle Scholar
  • 12 Blackwood L, Murphy S, Buracco P. et al. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol 2012; 10 (03) e1-e29
    CrossrefPubMedGoogle Scholar
  • 13 Govier SM. Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract 2003; 18 (02) 103-106
    CrossrefPubMedGoogle Scholar
  • 14 Selmic LE, Ruple A. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs. BMC Vet Res 2020; 16 (01) 1-6
    CrossrefPubMedGoogle Scholar
  • 15 McCaw DL, Miller MA, Ogilvie GK. et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994; 8 (06) 406-408
    CrossrefPubMedGoogle Scholar
  • 16 Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2008; 232 (01) 53-62
    CrossrefPubMedGoogle Scholar
  • 17 EMA. Produktinformationen: Stelfonta. Im Internet (Stand 31.08.2020): https://www.ema.europa.eu/en/documents/product-information/stelfonta-epar-product-information_de.pdf
    Google Scholar
  • 18 Boyle GM, DʼSouza MM, Pierce CJ. et al. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PloS One 2014; 9 (10) e108887
    CrossrefPubMedGoogle Scholar
  • 19 De Ridder TR, Campbell JE, Burke-Schwarz C. et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). J Vet Intern Med. 2020
    PubMedGoogle Scholar
  • 20 Hottendorf GH, Nielsen SW. Canine mastocytoma – a review of clinical aspects. J Am Vet Med Assoc 1969; 154 (08) 917-924
    PubMedGoogle Scholar